MEDNAX Company Profile (NYSE:MD)


MEDNAX logoMEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialized Health Services
  • Sub-Industry: Health Care Services
  • Symbol: NYSE:MD
  • CUSIP: 58502B10
  • Web:
  • Market Cap: $5.07 billion
  • Outstanding Shares: 92,360,000
Average Prices:
  • 50 Day Moving Avg: $59.90
  • 200 Day Moving Avg: $65.81
  • 52 Week Range: $53.80 - $76.96
  • Trailing P/E Ratio: 16.39
  • Foreward P/E Ratio: 13.72
  • P/E Growth: 1.05
Sales & Book Value:
  • Annual Revenue: $3.27 billion
  • Price / Sales: 1.55
  • Book Value: $29.91 per share
  • Price / Book: 1.84
  • EBIDTA: $648.78 million
  • Net Margins: 10.21%
  • Return on Equity: 13.59%
  • Return on Assets: 7.06%
  • Debt-to-Equity Ratio: 0.73%
  • Current Ratio: 1.44%
  • Quick Ratio: 1.39%
  • Average Volume: 972,211 shs.
  • Beta: 0.67
  • Short Ratio: 12.96

Frequently Asked Questions for MEDNAX (NYSE:MD)

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) released its earnings results on Thursday, May, 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.01. The business had revenue of $835.60 million for the quarter, compared to analyst estimates of $837.01 million. MEDNAX had a return on equity of 13.59% and a net margin of 10.21%. The company's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 earnings per share. View MEDNAX's Earnings History.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX updated its second quarter earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $0.85-0.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.00.

Where is MEDNAX's stock going? Where will MEDNAX's stock price be in 2017?

9 brokerages have issued 1-year price targets for MEDNAX's shares. Their forecasts range from $58.00 to $72.00. On average, they expect MEDNAX's share price to reach $65.57 in the next twelve months. View Analyst Ratings for MEDNAX.

What are analysts saying about MEDNAX stock?

Here are some recent quotes from research analysts about MEDNAX stock:

  • 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (4/27/2017)
  • 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)

Are investors shorting MEDNAX?

MEDNAX saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 7,120,627 shares, a decrease of 24.9% from the April 13th total of 9,480,171 shares. Based on an average daily trading volume, of 1,584,427 shares, the days-to-cover ratio is currently 4.5 days. Currently, 7.8% of the company's stock are sold short.

Who are some of MEDNAX's key competitors?

Who owns MEDNAX stock?

MEDNAX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.87%), Vanguard Group Inc. (8.10%), FMR LLC (5.73%), Longview Partners Guernsey LTD (4.91%), State Street Corp (3.19%) and Nordea Investment Management AB (2.80%). Company insiders that own MEDNAX stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Roger Md Medel and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

Who sold MEDNAX stock? Who is selling MEDNAX stock?

MEDNAX's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Mawer Investment Management Ltd., TimesSquare Capital Management LLC, Goldman Sachs Group Inc., Handelsbanken Fonder AB, Columbia Wanger Asset Management LLC, Bank of Montreal Can and Teachers Advisors LLC. Company insiders that have sold MEDNAX stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.

Who bought MEDNAX stock? Who is buying MEDNAX stock?

MEDNAX's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Longview Partners Guernsey LTD, Victory Capital Management Inc., Fiduciary Management Inc. WI, Vanguard Group Inc., Dimensional Fund Advisors LP and Morgan Stanley. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

How do I buy MEDNAX stock?

Shares of MEDNAX can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MEDNAX stock cost?

One share of MEDNAX stock can currently be purchased for approximately $54.89.

Analyst Ratings

Consensus Ratings for MEDNAX (NYSE:MD) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings
Consensus Rating:Hold (Score: 1.89)
Consensus Price Target: $65.57 (19.46% upside)

Analysts' Ratings History for MEDNAX (NYSE:MD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Stifel NicolausLower Price TargetHold$65.00 -> $58.00LowView Rating Details
5/4/2017Bank of America CorpDowngradeBuy -> UnderperformLowView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHold$58.00LowView Rating Details
3/21/2017Robert W. BairdDowngradeOutperform -> Neutral$72.00HighView Rating Details
3/10/2017JPMorgan Chase & Co.Reiterated RatingOverweight -> Neutral$69.00LowView Rating Details
12/9/2016Goldman Sachs Group IncInitiated CoverageNeutral$66.00N/AView Rating Details
11/9/2016MizuhoDowngradeBuy -> Neutral$69.00 -> $64.00N/AView Rating Details
10/27/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
8/17/2016Citigroup IncLower Price TargetNeutral$76.00 -> $72.00N/AView Rating Details
3/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$76.00N/AView Rating Details
3/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$94.00 -> $70.00N/AView Rating Details
12/2/2015StephensReiterated RatingEqual Weight$77.00N/AView Rating Details
9/20/2015William BlairReiterated RatingBuyN/AView Rating Details
7/31/2015Dougherty & CoBoost Price TargetBuy$88.00 -> $90.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for MEDNAX (NYSE:MD)
Earnings by Quarter for MEDNAX (NYSE:MD)
Earnings History by Quarter for MEDNAX (NYSE:MD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$0.74$0.75$837.01 million$835.60 millionViewN/AView Earnings Details
2/7/2017Q416$1.06$1.00$842.15 million$831.00 millionViewListenView Earnings Details
10/27/2016Q316$1.05$1.09$821.18 million$828.00 millionViewListenView Earnings Details
7/28/2016Q216$1.07$1.03$775.68 million$772.00 millionViewListenView Earnings Details
4/28/2016Q116$0.86$0.87$741.49 million$752.60 millionViewListenView Earnings Details
2/4/2016Q415$1.10$1.13$748.02 million$742.00 millionViewListenView Earnings Details
10/29/2015Q315$0.97$1.10$730.63 million$722.30 millionViewListenView Earnings Details
7/30/2015Q215$0.88$0.97$677.02 million$676.60 millionViewListenView Earnings Details
4/30/2015Q115$0.71$0.72$641.24 million$639.40 millionViewListenView Earnings Details
1/29/2015Q414$0.87$0.89$637.90 million$651.00 millionViewListenView Earnings Details
10/30/2014Q314$0.85$0.86$619.61 million$627.00 millionViewListenView Earnings Details
7/31/2014Q214$0.78$0.79$603.00 million$595.54 millionViewListenView Earnings Details
5/1/2014Q114$0.63$0.63$574.80 million$566.00 millionViewListenView Earnings Details
1/30/2014Q4$0.75$0.20$555.30 million$567.00 millionViewListenView Earnings Details
10/31/2013Q313$1.48$1.52$556.63 million$555.00 millionViewListenView Earnings Details
7/30/2013Q2 2013$1.36$1.37$533.39 million$529.18 millionViewListenView Earnings Details
5/2/2013Q1 2013$1.09$1.10$504.24 million$502.70 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.30$1.32$473.70 million$471.30 millionViewListenView Earnings Details
11/1/2012Q312$1.28$1.32$470.60 million$473.10 millionViewN/AView Earnings Details
7/31/2012$1.19$1.22ViewN/AView Earnings Details
5/3/2012$1.00$0.98ViewN/AView Earnings Details
2/2/2012$1.19$1.19ViewN/AView Earnings Details
11/1/2011$1.18$1.19ViewN/AView Earnings Details
8/2/2011$1.15$1.15ViewN/AView Earnings Details
5/3/2011$0.91$0.94ViewN/AView Earnings Details
2/3/2011$1.12$1.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MEDNAX (NYSE:MD)
2017 EPS Consensus Estimate: $3.95
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.80$0.81$0.81
Q2 20172$0.99$1.00$1.00
Q3 20173$1.07$1.09$1.08
Q4 20173$1.05$1.09$1.07
(Data provided by Zacks Investment Research)


Dividend History for MEDNAX (NYSE:MD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MEDNAX (NYSE:MD)
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 99.16%
Insider Trades by Quarter for MEDNAX (NYSE:MD)
Institutional Ownership by Quarter for MEDNAX (NYSE:MD)
Insider Trades by Quarter for MEDNAX (NYSE:MD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2017Manuel KadreDirectorBuy21,704$55.79$1,210,866.16View SEC Filing  
5/5/2017Vivian Lopez-BlancoCFOSell7,778$55.82$434,167.96View SEC Filing  
2/23/2017Enrique SosaDirectorSell10,668$69.65$743,026.20View SEC Filing  
2/17/2017Vivian Lopez-BlancoCFOSell15,164$70.01$1,061,631.64View SEC Filing  
2/16/2017Dominic J AndreanoSVPSell6,000$69.59$417,540.00View SEC Filing  
2/16/2017John C PepiaInsiderSell2,500$69.58$173,950.00View SEC Filing  
2/16/2017Paul G GabosDirectorSell21,336$69.63$1,485,625.68View SEC Filing  
2/10/2017Md Pascal J GoldschmidtDirectorSell25,294$67.82$1,715,439.08View SEC Filing  
2/9/2017Md Carlo A WaldemarDirectorSell5,334$67.90$362,178.60View SEC Filing  
1/17/2017Vivian Lopez-BlancoCFOSell10,000$70.95$709,500.00View SEC Filing  
12/7/2016Md Pascal J GoldschmidtDirectorBuy2,100$66.52$139,692.00View SEC Filing  
9/14/2016Md Pascal J GoldschmidtDirectorSell1,500$65.01$97,515.00View SEC Filing  
6/13/2016Dominic J AndreanoSVPSell3,922$68.80$269,833.60View SEC Filing  
6/8/2016Md Carlo A WaldemarDirectorSell5,334$70.50$376,047.00View SEC Filing  
6/7/2016Karl B WagnerInsiderSell27,482$68.45$1,881,142.90View SEC Filing  
6/1/2016Joseph M CalabroCOOSell28,347$67.78$1,921,359.66View SEC Filing  
6/1/2016Michael D StanleyInsiderSell14,778$67.78$1,001,652.84View SEC Filing  
5/16/2016Dominic J AndreanoSVPSell3,000$68.53$205,590.00View SEC Filing  
5/2/2016Vivian Lopez-BlancoCFOSell9,350$71.22$665,907.00View SEC Filing  
3/11/2016Md Pascal J GoldschmidtDirectorSell3,100$65.00$201,500.00View SEC Filing  
2/29/2016Paul G GabosDirectorSell10,668$67.15$716,356.20View SEC Filing  
12/11/2015Md Pascal J. GoldschmidtDirectorSell5,250$70.99$372,697.50View SEC Filing  
9/8/2015Cesar L. AlvarezDirectorSell10,668$81.00$864,108.00View SEC Filing  
8/27/2015Roger Md MedelCEOSell100,000$80.27$8,027,000.00View SEC Filing  
6/8/2015Karl B WagnerInsiderSell37,820$70.28$2,657,989.60View SEC Filing  
6/3/2015Joseph M CalabroCOOSell108,071$70.51$7,620,086.21View SEC Filing  
3/9/2015Md Pascal J GoldschmidtDirectorSell8,500$71.25$605,625.00View SEC Filing  
2/26/2015Roger Md MedelCEOSell100,000$71.61$7,161,000.00View SEC Filing  
2/20/2015Md Carlo A WaldemarDirectorSell10,668$71.50$762,762.00View SEC Filing  
2/6/2015Dominic J AndreanoSVPSell3,200$70.75$226,400.00View SEC Filing  
2/6/2015Vivian Lopez-BlancoCFOSell8,250$69.95$577,087.50View SEC Filing  
2/2/2015Paul G GabosDirectorSell17,584$68.07$1,196,942.88View SEC Filing  
1/30/2015William C HawkCOOSell3,598$68.50$246,463.00View SEC Filing  
11/14/2014Roger Md MedelCEOSell51,290$62.59$3,210,241.10View SEC Filing  
11/13/2014Roger Md MedelCEOSell63,440$62.55$3,968,172.00View SEC Filing  
11/7/2014Roger Md MedelCEOSell128,833$62.60$8,064,945.80View SEC Filing  
11/5/2014Roger Md MedelCEOSell169,845$62.60$10,632,297.00View SEC Filing  
11/4/2014Roger Md MedelCEOSell15,052$62.52$941,051.04View SEC Filing  
11/3/2014Roger Md MedelCEOSell10,881$62.52$680,280.12View SEC Filing  
10/31/2014Roger Md MedelCEOSell61,592$62.58$3,854,427.36View SEC Filing  
10/30/2014Karl B WagnerInsiderSell40,000$62.50$2,500,000.00View SEC Filing  
10/30/2014Vivian Lopez-BlancoCFOSell8,800$60.00$528,000.00View SEC Filing  
7/30/2014Karl B WagnerInsiderSell80,000$60.00$4,800,000.00View SEC Filing  
6/10/2014Dominic J AndreanoSVPSell2,252$58.48$131,696.96View SEC Filing  
6/6/2014Karl B WagnerInsiderSell44,596$58.53$2,610,203.88View SEC Filing  
6/5/2014William C HawkCOOSell6,911$57.66$398,488.26View SEC Filing  
6/2/2014David A ClarkCOOSell16,230$57.00$925,110.00View SEC Filing  
6/2/2014Michael D StanleyInsiderSell18,006$57.00$1,026,342.00View SEC Filing  
5/9/2014Karl WagnerInsiderSell79,524$57.09$4,540,025.16View SEC Filing  
5/9/2014Md Pascal GoldschmidtDirectorSell30,000$57.11$1,713,300.00View SEC Filing  
5/8/2014Joseph CalabroCOOSell137,500$57.06$7,845,750.00View SEC Filing  
2/20/2014Dominic AndreanoSVPSell3,000$61.00$183,000.00View SEC Filing  
2/10/2014Joseph CalabroCOOSell150,000$55.55$8,332,500.00View SEC Filing  
2/10/2014Md Carlo WaldemarDirectorSell10,668$55.40$591,007.20View SEC Filing  
11/7/2013Enrique SosaDirectorSell5,334$107.00$570,738.00View SEC Filing  
11/7/2013Karl WagnerInsiderSell1,800$107.60$193,680.00View SEC Filing  
9/11/2013William C HawkCOOSell3,162$100.62$318,160.44View SEC Filing  
9/10/2013Dominic J AndreanoSVPSell3,718$99.63$370,424.34View SEC Filing  
8/7/2013Karl WagnerInsiderSell25,000$98.01$2,450,250.00View SEC Filing  
8/2/2013Joseph M CalabroCOOSell36,154$98.57$3,563,699.78View SEC Filing  
6/3/2013David A ClarkCOOSell8,645$91.01$786,781.45View SEC Filing  
6/3/2013Michael D StanleyInsiderSell8,906$91.01$810,535.06View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MEDNAX (NYSE:MD)
Latest Headlines for MEDNAX (NYSE:MD)
DateHeadline logoOversold Conditions For Mednax (MD) - May 26 at 7:16 PM logoMEDNAX Inc (MD) Receives Consensus Rating of "Hold" from Brokerages - May 26 at 2:52 PM logoMEDNAX Inc (MD) Price Target Cut to $58.00 by Analysts at Stifel Nicolaus - May 25 at 10:41 AM logoMEDNAX Inc (MD) Downgraded to "C+" at TheStreet - May 19 at 1:38 PM logoShort Interest in MEDNAX Inc (MD) Drops By 24.9% - May 16 at 7:14 AM logoInsider Selling: MEDNAX Inc (MD) CFO Sells 7,778 Shares of Stock - May 8 at 7:36 PM logoMEDNAX Inc (MD) Director Buys $1,210,866.16 in Stock - May 8 at 7:17 PM logoMEDNAX Inc (MD) Expected to Post Quarterly Sales of $859.84 Million - May 6 at 9:53 AM logoMEDNAX (MD) Receives Daily Media Sentiment Score of 0.07 - May 5 at 11:45 PM logoEdited Transcript of MD earnings conference call or presentation 4-May-17 2:00pm GMT - May 4 at 11:34 PM logoMEDNAX Inc (MD) Rating Lowered to Underperform at Bank of America Corp - May 4 at 10:56 PM logoMEDNAX Inc (MD) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - May 4 at 9:48 PM logoMEDNAX Inc (MD) Issues Q2 Earnings Guidance - May 4 at 12:04 PM logoMEDNAX Reports First Quarter GAAP EPS of $0.59; Adjusted EPS of $0.75 - May 4 at 11:45 AM logoMEDNAX Inc (MD) Expected to Post Earnings of $0.99 Per Share - May 4 at 7:46 AM logoMednax misses by $0.13, misses on revenue - May 4 at 6:07 AM logoSpecialized Health Services Stocks on Investors' Radar -- DaVita, Acadia Healthcare, HealthSouth, and MEDNAX - May 3 at 5:33 PM logoMEDNAX (MD) Receives Coverage Optimism Score of 0.11 - May 2 at 5:04 PM logoMEDNAX Inc (MD) Receives Average Rating of "Hold" from Analysts - May 1 at 6:36 PM logoSomewhat Favorable News Coverage Unlikely to Impact MEDNAX (MD) Stock Price - April 29 at 9:57 PM logoMEDNAX Inc (MD) Upgraded by Zacks Investment Research to "Hold" - April 28 at 8:02 PM logoMEDNAX Inc (MD) Upgraded at Zacks Investment Research - April 28 at 1:06 AM logoMEDNAX (MD) Given Media Sentiment Score of 0.21 - April 27 at 1:13 AM logoMEDNAX Inc (MD) Lifted to Hold at Zacks Investment Research - April 23 at 7:26 PM logoMEDNAX (MD) Getting Somewhat Positive Press Coverage, Study Shows - April 23 at 7:21 PM logoMEDNAX to Exhibit at Ambulatory Surgery Center Association 2017 - April 21 at 10:01 AM logoMEDNAX Inc (MD) Releases Q1 Earnings Guidance - April 20 at 10:10 AM logoMEDNAX Previews 2017 First Quarter Results - April 20 at 10:07 AM logoMednax misses Street 1Q forecasts - April 20 at 7:53 AM logo3 Hospital Stocks That Won't Make You Feel Better in Q1 - April 19 at 6:32 PM logoSomewhat Positive Media Coverage Extremely Likely to Impact MEDNAX (MD) Share Price - April 17 at 10:18 PM logoMEDNAX Inc (MD) Raised to "Hold" at Zacks Investment Research - April 13 at 9:58 PM logo$0.82 EPS Expected for MEDNAX Inc (MD) This Quarter - April 13 at 8:44 AM logoBrokers Set Expectations for MEDNAX Inc's Q2 2017 Earnings (MD) - April 13 at 8:39 AM logoMEDNAX to Present as a Corporate Partner at Becker’s Hospital Review 8th Annual Meeting - April 12 at 7:25 PM logoMEDNAX's (MD) "Hold" Rating Reaffirmed at Jefferies Group LLC - April 10 at 5:12 PM logoMEDNAX Inc (MD) Stock Rating Lowered by Zacks Investment Research - April 2 at 9:14 AM logoMednax Reaches Analyst Target Price - March 27 at 5:59 PM logoRobert W. Baird Lowers MEDNAX Inc (MD) to Neutral - March 25 at 12:46 PM logoZacks Investment Research Lowers MEDNAX Inc (MD) to Sell - March 23 at 11:57 PM logoMEDNAX Announces Acquisition of Ophthalmology Practice in Nevada - March 23 at 7:02 PM logoMEDNAX downgraded by Robert W. Baird - March 21 at 6:26 PM logoBirth Trends Are Not Mednax's Friend; Baird Downgrades - March 21 at 3:17 PM logoMEDNAX Inc (MD) Upgraded to “Hold” at Zacks Investment Research - March 14 at 8:31 AM logo6:45 am MEDNAX acquires Midwest Perinatal Associates for an undisclosed sum; expected to be immediately accretive to earnings - March 13 at 10:26 AM logoMEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Kansas - March 13 at 10:26 AM logoMEDNAX downgraded by JP Morgan - March 10 at 7:43 PM logoObamacare Replacement: A Threat to Hospital Stocks? - March 8 at 7:11 PM logoPost Earnings Coverage as DaVita's Quarterly Revenue Increased 5.2% - March 7 at 10:29 AM logoMednax (MD) Presents At The Raymond James 38th Annual Institutional Investors Conference 2017 - March 6 at 6:00 PM



MEDNAX (MD) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff